Are Analysts Bullish Integra LifeSciences Holdings Corporation (NASDAQ:IART) After Last Week?

July 16, 2018 - By Jason Dias

Investors sentiment decreased to 0.92 in 2018 Q1. Its down 0.06, from 0.98 in 2017Q4. It turned negative, as 21 investors sold Integra LifeSciences Holdings Corporation shares while 75 reduced holdings. 37 funds opened positions while 51 raised stakes. 69.24 million shares or 1.40% less from 70.22 million shares in 2017Q4 were reported.
Fisher Asset Ltd Liability Corporation has invested 0.08% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Global X Management Communications Ltd Com accumulated 0% or 746 shares. Goldman Sachs reported 1.12 million shares or 0.02% of all its holdings. De Burlo Gru Incorporated reported 0.14% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Adage Prtn Grp Ltd Limited Liability Company reported 0.04% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). 59 are held by Trust Department Mb Commercial Bank N A. Royal Bank Of Canada, Ontario – Canada-based fund reported 606,698 shares. Fdx Advisors stated it has 7,586 shares or 0.01% of all its holdings. Schwab Charles Investment has invested 0.02% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Koch holds 0.07% or 12,790 shares in its portfolio. Northwest Inv Counselors stated it has 0.17% of its portfolio in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Ameriprise Financial holds 0.01% or 426,915 shares. Us Bancshares De holds 0% of its portfolio in Integra LifeSciences Holdings Corporation (NASDAQ:IART) for 26,152 shares. Cardinal Cap Management stated it has 17,535 shares or 0.3% of all its holdings. Stone Ridge Asset Mngmt holds 0.02% or 7,526 shares.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Ratings Coverage

Among 7 analysts covering Integra Lifesciences (NASDAQ:IART), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. Integra Lifesciences had 9 analyst reports since February 28, 2018 according to SRatingsIntel. The firm has “Neutral” rating given on Tuesday, May 22 by JP Morgan. JP Morgan maintained the shares of IART in report on Thursday, April 26 with “Neutral” rating. Jefferies maintained the shares of IART in report on Wednesday, April 25 with “Buy” rating. The stock of Integra LifeSciences Holdings Corporation (NASDAQ:IART) earned “Market Outperform” rating by JMP Securities on Wednesday, February 28. The rating was maintained by Cantor Fitzgerald on Wednesday, April 25 with “Hold”. The firm has “Buy” rating by Oppenheimer given on Thursday, March 29. Citigroup downgraded it to “Neutral” rating and $66 target in Monday, July 2 report. The rating was maintained by JP Morgan on Wednesday, April 11 with “Neutral”. Below is a list of Integra LifeSciences Holdings Corporation (NASDAQ:IART) latest ratings and price target changes.

02/07/2018 Broker: Citigroup Old Rating: Buy New Rating: Neutral Old Target: $64 New Target: $66 Downgrade
22/05/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $57 New Target: $65 Maintain
25/04/2018 Broker: Jefferies Rating: Buy New Target: $70.0000 Maintain
26/04/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $55 New Target: $57 Maintain
25/04/2018 Broker: Cantor Fitzgerald Rating: Hold New Target: $52.0000 Maintain
11/04/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Neutral Old Target: $50 New Target: $55 Maintain
05/04/2018 Broker: BTIG Research Rating: Neutral New Target: $56 Initiates Coverage On
29/03/2018 Broker: Oppenheimer Rating: Buy New Target: $58.0000 Maintain
28/02/2018 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Outperform Old Target: $57 New Target: $60 Maintain

The stock decreased 0.60% or $0.38 during the last trading session, reaching $62.62. About 224,156 shares traded. Integra LifeSciences Holdings Corporation (NASDAQ:IART) has risen 28.46% since July 16, 2017 and is uptrending. It has outperformed by 15.89% the S&P500.

Integra LifeSciences Holdings Corporation develops, makes, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company has market cap of $5.32 billion. The firm operates through two divisions, Specialty Surgical Solutions; and Orthopedics and Tissue Technologies. It has a 71.32 P/E ratio. It offers neurosurgery and critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.

More important recent Integra LifeSciences Holdings Corporation (NASDAQ:IART) news were published by: Benzinga.com which released: “Benzinga’s Top Upgrades, Downgrades For July 2, 2018” on July 02, 2018, also Seekingalpha.com published article titled: “Premarket analyst action – healthcare”, Globenewswire.com published: “Market Trends Toward New Normal in Applied Optoelectronics, Integra LifeSciences, Medtronic, Workhorse Group …” on June 29, 2018. More interesting news about Integra LifeSciences Holdings Corporation (NASDAQ:IART) was released by: Nasdaq.com and their article: “Integra LifeSciences to Host Second Quarter 2018 Earnings Results Conference Call on July 25, 2018” with publication date: July 11, 2018.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.